Rapid and accurate antibody testing on a large scale is vital to address the challenges of the COVID-19 pandemic. The Siemens Healthineers SARS-CoV-2 Total (COV2T) Assay* can be used effectively for broad population testing. There is the potential that broad population testing for antibodies may help re-open society in a smart way.
The COV2T assay produces results in as little as 10 minutes on the Atellica® IM Analyzer with a capacity to process up to 440 assays per hour† with the sensitivity and specificity laboratories have come to expect from us.
ADVIA Centaur XP/XPT
Simplified identification of immune response with a total assay
The COV2T assay detects both IgM and longer-lasting IgG antibodies with high sensitivity of recent and prior infection. This allows for identification of patients who have developed an adaptive immune response, which indicates recent infection or prior exposure.
Smart selection of the S1 RBD antigen to detect antibodies that block virus entry into cells
The COV2T assay uses a proven antibody-bridging assay architecture, which involves binding of a single SARS-CoV-2 antibody to two identical SARS-CoV-2 antigens, helping to avoid false-positive results. The human body produces antibodies against both the nucleocapsid (N) and spike (S) proteins as well as other proteins in the SARS-CoV-2 virus, but to be effective against the virus, the antibodies must be neutralizing.
Tests for detection of antibodies to both the N and S proteins (including the S1 RBD antigen) have been developed and indicate an immune response to infection. Growing evidence indicates that the spike protein antibodies are neutralizing, based on in vitro data.1 Evidence for neutralization antibodies to the N protein is currently sparse.
Siemens Healthineers smartly selected the receptor-binding domain (RBD) of the S1 spike protein to detect antibodies that block the virus entry into the cells. This selection is aligned with the current vaccinations in development that target the spike protein.
Reliable and rapid SARS-CoV-2 antibody testing on a large scale for both reference laboratories and acute care settings
The COV2T assay can be used with a full range of Siemens Healthineers systems such as:
- The Atellica® IM Analyzer*
- ADVIA Centaur® Immunoassay Systems*
- Dimension® and Dimension Vista® systems*
This enables accurate SARS-CoV-2 antibody testing on a massive scale for both reference laboratories and acute care settings. The test produces results rapidly—in as little as 10 minutes on the Atellica IM Analyzer, with a capacity to process up to 440 assays per hour.‡
With a global installed base of over 20,000 instruments§ and a manufacturing capability to produce over 50 million tests a month, Siemens Healthineers offers hope that the goal of effective management of the threat of COVID-19 is within reach.
“As one of the leading specialized laboratories, we recognized the critical need of our customers to have rapid and accurate testing to manage COVID-19 amongst their patients and staff. The Siemens Healthineers total antibody test enables us to confidently deliver fast, reliable results that will be extremely valuable in the surveillance of the disease.”
Paul F. Beyer, CEO of Ascend Clinical
Discuss comprehensive COVID-19 testing with a Siemens Healthineers expert.
Complete the form to download infographic and receive more information on COVID-19 testing solutions.
Did this information help you?
†Dependent on test mix.
‡For samples collected ≥14 days after positive PCR result.
§Installed base of ADVIA Centaur® XP, ADVIA Centaur XPT, ADVIA Centaur CP, Atellica® Solution, Dimension Vista®, and Dimension® EXL™ analyzers.
Chen X, et al. Cellular & Molecular Immunology. 2020 Apr. https://doi.org/10.1038/s41423-020-0426-7